Replies to post #178515 on Biotech Values

[mcbio]

ARQL

When he left I stopped him in the lobby and asked him about it and what he thought based on the metmab failure.

He said they took metmab through phase 3 based on a phase 2 trial with a lot of holes in it but he thought tivantinib should be further explored and has value

Thanks for the comments. I'd prefer that ARQL shares rebound nicely prior to the interim P3 readout (2H15? 2016?) as I'd rather be safe than sorry as I never trust Phase 3 results to be positive. That said, if valuation is still around here, I'll have no issue in holding through that binary. I am hopeful that we'll get some positive news from the rest of the pipeline before then as well.